This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Progenics Pharmaceuticals, Inc.
Drug Names(s): PRO 542
Description: PRO 542 belongs to a new class of drugs, viral entry inhibitors, which are intended to prevent HIV from entering and infecting cells. PRO 542 is an antibody-like molecule which is designed to neutralize HIV by directly binding to gp120, a protein on the surface of the virus, thereby preventing HIV attachment to healthy cells within the immune system. In previous Phase I/II studies in HIV-infected patients, intravenously administered PRO 542 mediated dose-dependent and statistically significant reductions in plasma HIV RNA, a measure of HIV “viral load.” PRO 542 is currently in Phase II clinical testing in HIV-infected adults and children.
PRO 542 is a fusion protein that incorporates the HIV-binding region of the human cell surface receptor CD4 into a human antibody-like molecule. PRO 542 is designed to neutralize HIV by binding to the HIV surface glycoprotein (gp120) and preventing the virus from attaching to host cells.
Deal Structure: In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Partners: Sanofi Formatech, Inc.
PRO 542 News
Additional information available to subscribers only: